Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

Must have received: all approved standard of care therapies for metastatic CRC — metastatic

have received, been ineligible for, intolerant to, or declined all approved standard of care (SOC) therapies for metastatic CRC

Cannot have received: any approved anti-cancer therapy including chemotherapy, targeted small molecule therapy, systemic immunotherapy, or radiation therapy

Exception: palliative radiotherapy for bone metastases or soft tissue lesions completed >7 days prior; hormone-replacement therapy or oral contraceptives; subjects with Grade 2 neuropathy or Grade 2 alopecia

Any approved anti-cancer therapy including chemotherapy, targeted small molecule therapy, systemic immunotherapy, or radiation therapy within 2 weeks prior to the first dose of study treatment; or if subject has not recovered (i.e., ≤ to Grade 1 or returned to baseline level) from AEs due to a previously administered agent; the following exceptions are allowed: * Palliative radiotherapy for bone metastases or soft tissue lesions should be completed >7 days prior to the first dose of study treatment. * Hormone-replacement therapy or oral contraceptives. * Subjects with Grade 2 neuropathy or Grade 2 alopecia.